Process for preparing tetracyclic heterocycle compounds

US9725464B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9725464-B2
Application numberUS-201415032552-A
CountryUS
Kind codeB2
Filing dateOct 24, 2014
Priority dateOct 30, 2013
Publication dateAug 8, 2017
Grant dateAug 8, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention is directed to a process for preparing Tetracyclic Heterocycle Compounds of formula (I): which are useful as HCV NS5A inhibitors. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).

First claim

Opening claim text (preview).

What is claimed is: 1. A process for preparing a compound of Formula I: and pharmaceutically acceptable salts thereof, wherein said process comprises: (A) (i) contacting the compound of Formula VI with bis(pinacoloato)diboron in the presence of an acetate or pivalate base, a transition metal catalyst, and optionally in the presence of a phosphorus ligand source, in a mixture of water and an organic solvent E, to provide an intermediate compound of Formula VII: then (ii) contacting the intermediate compound of formula VII with a compound of formula VIIb in the presence of a carbonate, acetate or pivalate base and a transition metal catalyst, and optionally in the presence of a phosphorus ligand source, in said mixture of water and organic solvent E, to provide a compound of formula VIII: wherein organic solvent E is selected from dimethylacetamide, toluene, acetonitrile, N,N-dimethylformamide, tetrahydrofuran, 2-methyl tetrahydrofuran, cyclopentyl methyl ether, isopropanol, ethanol, ethyl acetate, isopropyl acetate and dimethoxyethane; and (B) (i) contacting the di-p-nitrobenzoate salt of the compound of Formula VIII with an inorganic base, in an organic solvent F, for a time sufficient to remove the Boc protecting groups from the compound of Formula VIII, then (ii) contacting the deprotected compound in situ with HCl to provide a compound of Formula IX: wherein organic solvent F is selected from methanol, acetonitrile, tetrahydrofuran, 2-methyl tetrahydrofuran, ethanol, isopropanol and toluene; and (C) contacting the compound of Formula IX with: (i) an additive selected from 2-hydroxypyridine-N-oxide, N-hydroxysuccinimide, HOBt and pyridine, and (ii) a non-nucleophilic base) in the presence of (i) a compound of formula Xa: and (ii) an amide coupling reagent in an organic solvent G to provide a compound of Formula I: wherein organic solvent G is selected from tetrahydrofuran, N,N-dimethylformamide, dimethylacetamide, N-methylpyrrolidinone and dimethylsulfoxide; and wherein each occurrence of R 1 is independently C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl or C 6 -C 10 aryl; each occurrence of R 2 is independently C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, 3 to 7-membered monocyclic heterocycloalkyl or C 6 -C 10 aryl; R 3 is C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 6 -C 10 aryl, 5 or 6-membered monocyclic heteroaryl or 9 or 10-membered bicyclic heteroaryl, wherein said C 3 -C 7 cycloalkyl group, said C 6 -C 10 aryl group, said 5 or 6-membered monocyclic heteroaryl group or said 9 or 10-membered bicyclic heteroaryl group can be optionally substituted with up to three groups, each independently selected from C 1 -C 6 alkyl and C 3 -C 7 cycloalkyl; and R a is Br, Cl or I. 2. The process according to claim 1 , wherein: Step A, part (i) is conducted at a temperature in a range of from about 40° C. to about 110° C.; the organic solvent employed in step A, part (i) is N,N-dimethylformamide; the acetate or pivalate base employed in Step A, part (i) is selected from NaOAc, CsOAc, KOPiv, NaOPiv and potassium acetate; the transition metal catalyst employed in Step A, part (i) is selected from Pd 2 dba 3 , Pd(OAc) 2 and PdCl 2 ; the optional phosphine ligand employed in Step A, part (i) is selected from N-Bu(Ad) 2 P, Am-phos, n-BuP(t-Bu) 2 -HBF 4 , XPhos, SPhos, BrettPhos, DTBPF, PCy 3 and P(t-Bu) 3 ; Step A, part (ii) is conducted at a temperature in a range of from about 40° C. to about 110° C.; the organic solvent employed in step A, part (ii) is N,N-dimethylformamide; the carbonate, acetate or pivalate base employed in Step A, part (ii) is selected from K 2 CO 3 , NaOAc, CsOAc, KOPiv, NaOPiv and potassium acetate; the transition metal catalyst employed in Step A part (ii) is selected from Pd 2 dba 3 , Pd(OAc) 2 and PdCl 2 ; the optional phosphine ligand employed in Step A, part (ii) is selected from N-Bu(Ad) 2 P, Am-phos, n-BuP(t-Bu) 2 -HBF 4 , XPhos, SPhos, BrettPhos, DTBPF, PCy 3 and P(t-Bu) 3 ; Step B, part (i) is conducted at a temperature in a range of from about 0° C. to about 60° C.; the organic solvent employed in step B is N,N-dimethylformamide; the inorganic base employed in step B is selected from a carbonate base, a phosponate base or an alkali metal hydroxide base; Step B, part (ii) is conducted at a temperature in a range of from about 20° C. to about 60° C.; Step C is conducted at a temperature in a range of from about −10° C. to about 60° C.; the organic solvent employed in step C is N,N-dimethylformamide; the non-nucleophilic base employed in step C is selected from (N-methylmorpholine, triethylamine, diisopropylethylamine and pyridine; the amide coupling reagent employed in step C is selected from DCC, HATU, T3P and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride. 3. The process according to claim 1 , wherein each occurrence of R 1 and R 2 is independently C 1 -C 6 alkyl and R 3 is 5 or 6-membered heteroaryl or C 6 -C 10 aryl, wherein R 3 can be optionally substituted with a group selected from C 1 -C 6 alkyl and C 3 -C 7 cycloalkyl. 4. The process according to claim 1 , wherein: Step A, part (i) is conducted at a temperature in a range of from about 70° C. to about 90° C.; the organic solvent employed in step A, part (i) is a mixture of DME and water; the acetate or pivalate base employed in Step A, part (i) is selected from NaOAc, CsOAc and potassium acetate; the transition metal catalyst employed in Step A part (i) is Pd 2 dba 3 ; the optional phosphine ligand employed in Step A, part (i) is N-Bu(Ad) 2 P; Step A, part (ii) is conducted at a temperature in a range of from about 70° C. to about 90° C.; the organic solvent employed in step A, part (ii) is a mixture of DME and water; the carbonate, acetate or pivalate base employed in Step A, part (ii) is Na 2 CO 3 or K 2 CO 3 ; the transition metal catalyst employed in Step A, part (ii) is Pd 2 dba 3 ; the optional phosphine ligand employed in Step A, part (ii) is Am-phos; Step B, part (i) is conducted at a temperature in a range of from about 15° C. to about 30° C.; the organic solvent employed in step B is an organic alcohol; the inorganic base employed in step B is an alkali metal carbonate base; Step D, part (ii) is conducted at a temperature in a range of from about 35° C. to about 50° C.; Step C is conducted at a temperature in a range of from about 15° C. to about 35° C.; the organic solvent employed in step C is acetonitrile; the additive employed in step C is HOBt; the non-nucleophilic base employed in step C is N-methylmorpholine; the amide coupling reagent employed in step C is N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride. 5. The process according to claim 4 , wherein: Step A, part (i) is conducted at a temperature in a range of from about 70° C. to about 90° C.; the organic solvent employed in step A, part (i) is a mixture of DME and water; the acetate or pivalate base employed in Step A, part (i) is selected from NaOAc, CsOAc and potassium acetate; the tra

Assignees

Inventors

Classifications

  • Boronic and borinic acid compounds · CPC title

  • by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups · CPC title

  • C07D498/04Primary

    Ortho-condensed systems · CPC title

  • with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain · CPC title

  • directly linked by a ring-member-to-ring-member bond · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9725464B2 cover?
The present invention is directed to a process for preparing Tetracyclic Heterocycle Compounds of formula (I): which are useful as HCV NS5A inhibitors. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
Who is the assignee on this patent?
Merck Sharp & Dohme
What technology area does this patent fall under?
Primary CPC classification C07D498/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).